Adverum Biotechnologies Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Adverum Biotechnologies sono diminuiti a un tasso medio annuo di -6.9%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.3%. I ricavi sono cresciuti crescere a un tasso medio annuo di 1.2%.

Informazioni chiave

-6.9%

Tasso di crescita degli utili

3.2%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	1.2%
Rendimento del capitale proprio	-65.3%
Margine netto	-9,411.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 18

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31

Ripartizione dei ricavi e delle spese

Come Adverum Biotechnologies guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqCM:ADVM Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Sep 24	1	-94	36
30 Jun 24	0	-100	40
31 Mar 24	0	-113	48
31 Dec 23	4	-117	50
30 Sep 23	4	-126	48
30 Jun 23	4	-133	51
31 Mar 23	4	-146	52
31 Dec 22	0	-155	55
30 Sep 22	0	-156	57
30 Jun 22	0	-154	54
31 Mar 22	0	-155	62
31 Dec 21	8	-146	63
30 Sep 21	8	-149	66
30 Jun 21	8	-138	63
31 Mar 21	8	-123	52
31 Dec 20	0	-118	45
30 Sep 20	0	-99	39
30 Jun 20	0	-87	35
31 Mar 20	0	-73	32
31 Dec 19	0	-64	28
30 Sep 19	0	-61	25
30 Jun 19	1	-66	23
31 Mar 19	1	-70	25
31 Dec 18	2	-73	25
30 Sep 18	2	-72	22
30 Jun 18	2	-65	23
31 Mar 18	2	-57	18
31 Dec 17	2	-56	20
30 Sep 17	2	-64	22
30 Jun 17	2	-64	22
31 Mar 17	2	-114	20
31 Dec 16	1	-114	20
30 Sep 16	2	-105	19
30 Jun 16	2	-105	20
31 Mar 16	2	-53	23
31 Dec 15	2	-47	20
30 Sep 15	2	-44	20
30 Jun 15	1	-38	15
31 Mar 15	1	-36	11
31 Dec 14	1	-29	8
30 Sep 14	0	-22	5
30 Jun 14	0	-14	3
31 Mar 14	0	-7	2
31 Dec 13	0	-5	1

Guadagni di qualità: ADVM al momento non è redditizia.

Margine di profitto in crescita: ADVM al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ADVM non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 6.9% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ADVM nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ADVM non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: ADVM ha un Return on Equity negativo ( -65.3% ), in quanto al momento non è redditizio.

Adverum Biotechnologies Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Adverum Biotechnologies Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Price target decreased to US$3.67

Price target decreased to US$3.67

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

Price target increased to US$4.33

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Adverum Biotechnologies: An Uncertain Path Forward

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Independent Chairman recently bought US$99k worth of stock

New 90-day low: US$10.55

Analysts lower revenue estimates to US$230.0k

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

New 90-day high: US$14.36

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market